Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists

Current Atherosclerosis Reports
Ashish SarrajuJoshua W Knowles

Abstract

Cardiovascular disease is the leading cause of death among adults in the USA. Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) are known risk factors for cardiovascular disease. Despite the development of numerous effective anti-glycemic therapies, we have been unable to completely mitigate cardiovascular risk with glucose lowering alone, and prevention of cardiovascular disease in patients with diabetes is primarily achieved with the use of medications that address other risk factors such as anti-hypertensives or statins. Glucagon-like peptide-1 (GLP-1) is a key hormone in the pathophysiology of diabetes. GLP-1 agonists have been recently approved for the treatment of T2DM as well as for chronic weight management. In this review, we aim to explore the effects of GLP-1 agonists on cardiovascular health with a focus on cardiometabolic variables and cardiac function.

References

Feb 19, 1999·Lancet·D M Lloyd-JonesD Levy
Jun 25, 2004·American Heart Journal·Karen OkrainecMark J Eisenberg
Feb 7, 2009·Journal of the American College of Cardiology·Leo TimmersImo E Hoefer
Dec 15, 2010·BMC Endocrine Disorders·Deepson S ShyangdanNorman R Waugh
Sep 17, 2011·European Heart Journal·Jacob LønborgThomas Engstrøm
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Deepson S ShyangdanAlisa Snaith
Aug 1, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·P LiN Liu
Aug 16, 2014·International Journal of Cardiology·Masaaki KonishiKazuo Kimura
Aug 17, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Magali BalteauChristophe Beauloye
Oct 24, 2014·Cardiovascular Diabetology·Francisco Kerr Saraiva, Andrei C Sposito
Dec 4, 2014·International Journal of Cardiology·Michael GejlPeter Vestergaard
Jan 8, 2015·The Annals of Pharmacotherapy·Angela M Thompson, Jennifer M Trujillo
Feb 14, 2015·Journal of the American College of Cardiology·Eiichi AkiyamaHisao Ogawa

❮ Previous
Next ❯

Citations

Jul 1, 2017·Frontiers in Nutrition·Elena ZocchiJosep Bassaganya-Riera
Jun 11, 2018·Current Diabetes Reports·Dorrin Zarrin Khat, Mansoor Husain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.